On January 6, 2026, Amphastar Pharmaceuticals, Inc. entered a License Agreement with Hanxin for an exclusive license to develop corticotropin products in the U.S. and Canada, involving an upfront payment of $2 million, with potential payments up to $89 million based on milestones.